drugset / Trial / NCT04254640
Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML
NaSingle-groupOpen-labelTreatment
Summary
In this study, the investigators conducted a phase II trial that evaluated the efficacy and safety of cladribine in combination with modified CAG regimen (low-dose cytarabine and aclarubicin) in elderly patients with AML.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2023-06-01
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cladribine | Small molecule | 5 mg/m2 | Intravenous |
| Background | Aclarubicin | Small molecule | 10 mg | Intravenous |
| Background | Cytarabine | Small molecule | 10 mg/m2 | Subcutaneous |
| Background | G-CSF | Unknown | 300 ug | Subcutaneous |